Drug intelligence / Profile preview

AB-729 + nucleos(t)ide analogue + pegylated interferon alfa-2a

Development stage: Unknown
Lead developer: Arbutus Biopharma
Modality: Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous (for AB-729, Pegylated Interferon Alfa-2a), Oral (for Nucleos(t)ide Analogue)

Overview

This drug is a **combination therapy** consisting of **AB-729 (imdusiran)**, a nucleos(t)ide analogue (NA), and **pegylated interferon alfa-2a (PEG-IFN-α2a)**. AB-729 is a small interfering RNA (siRNA) therapeutic targeted at chronic hepatitis B virus (cHBV) infection, designed to reduce all HBV viral proteins and antigens, particularly hepatitis B surface antigen (HBsAg), thereby helping reawaken the patient’s immune response[1][2][5]. It uses N-acetylgalactosamine (GalNAc) conjugation for targeted delivery to hepatocytes and is administered subcutaneously. Nucleos(t)ide analogues inhibit HBV DNA polymerase, reducing viral replication. Pegylated interferon alfa-2a is an immunomodulatory cytokine that enhances the host's antiviral immune response. The combination regimen aims to achieve a functional cure of chronic hepatitis B by using **complementary antiviral and immunomodulatory mechanisms**[1][3][4][5]. Primary indication is **chronic hepatitis B**.

Other names: imdusiran

Targets

HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on AB-729 + nucleos(t)ide analogue + pegylated interferon alfa-2a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-729 + nucleos(t)ide analogue + pegylated interferon alfa-2a.

Explore the full profile